Literature DB >> 28729287

BP Targets in CKD, Mortality, and SPRINT: What Have We Learned?

Stephen C Textor1, Gary L Schwartz2.   

Abstract

Entities:  

Keywords:  CKD; hypertension; mortality; targets

Mesh：

Substances：

Year:  2017        PMID： 28729287      PMCID： PMC5576952          DOI： 10.1681/ASN.2017060652

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  15 in total

1.  Redefining Blood-Pressure Targets--SPRINT Starts the Marathon.

Authors:  Vlado Perkovic; Anthony Rodgers
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

Review 2.  Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients.

Authors:  Chirag Bavishi; Sripal Bangalore; Franz H Messerli
Journal:  J Am Coll Cardiol       Date:  2017-02-07       Impact factor: 24.094

3.  Age and Outcomes Associated with BP in Patients with Incident CKD.

Authors:  Csaba P Kovesdy; Ahmed Alrifai; Elvira O Gosmanova; Jun Ling Lu; Robert B Canada; Barry M Wall; Adriana M Hung; Miklos Z Molnar; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-21       Impact factor: 8.237

4.  Hypertension in 2017-What Is the Right Target?

Authors:  Aram V Chobanian
Journal:  JAMA       Date:  2017-02-14       Impact factor: 56.272

5.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

7.  Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.

Authors:  O R Benavente; C S Coffey; R Conwit; R G Hart; L A McClure; L A Pearce; P E Pergola; J M Szychowski
Journal:  Lancet       Date:  2013-05-29       Impact factor: 79.321

8.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

9.  Effects of Intensive BP Control in CKD.

Authors:  Alfred K Cheung; Mahboob Rahman; David M Reboussin; Timothy E Craven; Tom Greene; Paul L Kimmel; William C Cushman; Amret T Hawfield; Karen C Johnson; Cora E Lewis; Suzanne Oparil; Michael V Rocco; Kaycee M Sink; Paul K Whelton; Jackson T Wright; Jan Basile; Srinivasan Beddhu; Udayan Bhatt; Tara I Chang; Glenn M Chertow; Michel Chonchol; Barry I Freedman; William Haley; Joachim H Ix; Lois A Katz; Anthony A Killeen; Vasilios Papademetriou; Ana C Ricardo; Karen Servilla; Barry Wall; Dawn Wolfgram; Jerry Yee
Journal:  J Am Soc Nephrol       Date:  2017-06-22       Impact factor: 10.121

10.  Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.

Authors:  John J Sim; Simran K Bhandari; Jiaxiao Shi; Kristi Reynolds; David A Calhoun; Kamyar Kalantar-Zadeh; Steven J Jacobsen
Journal:  Kidney Int       Date:  2015-05-06       Impact factor: 10.612
View more
  1 in total

1.  Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics.

Authors:  Roberto Minutolo; Luca De Nicola; Ciro Gallo; Paolo Chiodini; Michele Provenzano; Giuseppe Conte; Carlo Garofalo; Silvio Borrelli
Journal:  J Nephrol       Date:  2019-01-23       Impact factor: 3.902
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.